Copyright © 2017 American Academy of Pediatrics.

Slides:



Advertisements
Similar presentations
25/8/2012 PERTUSSIS VACCINE FOR ADOLESCENTS CAN WE AFFORD TO BE COMPLACENT? YASH PAUL JAIPUR.
Advertisements

Tetanus.
Tetanus and Tetanus Toxoid Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention.
Biology of Toxin Spring 2007 Thu Pham Nghi Tran Hong Nguyen.
Adult Immunization 2010 Tetanus, Diphtheria and Pertussis Segment This material is in the public domain This information is valid as of May 25, 2010.
Pediatric Immunization (EPI) Garcia, Garzon, Gaspar, Gatchalian, Gaw, Geraldoy, Geronimo, Geronimo, Geronimo.
Tetanus and Tetanus Toxoid Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Tetanus and Tetanus Toxoid Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention.
<Disease review>
Copyright © 2016 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Paula Stagg, RNMN WH IPAC Specialist Tracey Reid, RN WH ICP
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2000 American Medical Association. All rights reserved.
Tetanus/diptheria/pertussis (TDaP)
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Tetanus (Lockjaw).
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
TETANUS.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2012 American Medical Association. All rights reserved.
Immunogenicity and Safety of a Combination Diphtheria, Tetanus Toxoid, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine Coadministered.
Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection  Howard M. Rosenblatt,
Copyright © 2017 American Academy of Pediatrics.
Tetanus.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Tetanus.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2018 American Academy of Pediatrics.
Copyright © 2018 American Academy of Pediatrics.
Copyright © 2018 American Academy of Pediatrics.
Tetanus neonatorum.
Copyright © 2018 American Academy of Pediatrics.
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine From the Advisory Committee on Immunization.
Number of catch-up doses needed (n = 200) at admission and at 1-month follow-up by vaccine type among 95 children found to be underimmunized per ACIP guidelines.
Tetanus.
Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection  Howard M. Rosenblatt,
Presentation transcript:

Copyright © 2017 American Academy of Pediatrics. From: Tetanus Red Book® 2015, 2015 Figure Legend: Tetanus is caused by a neurotoxin from the anaerobic bacterium Clostridium tetani and is characterized by muscle spasms that often are worsened by noise or other external stimuli. The muscle spasms can progress from mild to severe over a 1-week period. Severe spasms subside over a period of weeks if the patient survives. The clinical manifestations of tetanus include localized tetanus (local muscle spasm in areas contiguous with the infected wound), cephalic tetanus (dysfunction of the cranial nerves in association with a wound on the head or neck), and generalized tetanus (full body involvement). Neonatal tetanus remains prevalent in areas of the world where mothers have not been vaccinated and local umbilical cord care is poor. The diagnosis is made clinically, and treatment includes the use of human tetanus immune globulin, oral antimicrobial agents (metronidazole or penicillin) for 10 to 14 days, and other supportive measures (eg, ventilatory support, decreased external stimuli such as loud noises). In addition, all infected wounds should be cleaned properly and debrided. Tetanus is prevented best through immunization with tetanus toxoid. Tetanus toxoid is available: (1) in combination with diphtheria toxoid and acellular pertussis vaccine (DTaP) to provide basic immunity against tetanus, diphtheria, and pertussis; (2) as part of a double antigen (DT) for children up to 6 years of age who cannot receive the pertussis component of the DTaP; and (3) as a single antigen (tetanus toxoid [TT]) or Tdap vaccine to immunize pregnant women and women of childbearing age to prevent tetanus in their newborns. DT must be replaced with Td or Tdap, which has a reduced diphtheria toxoid content, for patients older than 7 years to lessen the adverse effects associated with the use of the higher-dose diphtheria toxin. For most indications, TT is administered in combination with a diphtheria toxoid-containing preparation. Courtesy of H. Cody Meissner, MD, FAAP Date of download: 10/16/2017 Copyright © 2017 American Academy of Pediatrics. All rights reserved.